3
ALL3
Eurofarma Laboratorios S.AYear
3
ALL1
20221
20211
2020DEALS // DEV.
3
ALL3
DealsCountry
3
ALL1
SOUTH KOREA1
U.S.A1
UNITED KINGDOM3
ALL1
Pacira BioSciences1
SK Biopharmaceuticals1
Summit TherapeuticsTherapeutic Area
3
ALL1
Infections and Infectious Diseases2
NeurologyStudy Phase
3
ALL2
Approved1
Phase IIIDeal Type
3
ALL1
Agreement1
Collaboration1
Licensing AgreementProduct Type
3
ALL3
Small moleculeDosage Form
2
ALL1
Injectable Suspension1
TabletLead Product
3
ALL1
Bupivacaine1
Cenobamate1
RidinilazoleTarget
3
ALL1
Cell Division1
GABA A receptor1
Sodium channelLead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : SK Biopharmaceuticals
Deal Size : $62.0 million
Deal Type : Licensing Agreement
SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America
Details : Under the terms of agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize Xcopri (cenobamate) in Latin America. SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asia, a...
Product Name : Xcopri
Product Type : Small molecule
Upfront Cash : $15.0 million
July 14, 2022
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : SK Biopharmaceuticals
Deal Size : $62.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Pacira BioSciences
Deal Size : Undisclosed
Deal Type : Agreement
Pacira BioSciences Signs Exparel Distribution Agreement With Eurofarma in Latin America
Details : Under the terms of the agreement, Eurofarma obtains the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico.
Product Name : Exparel
Product Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Pacira BioSciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Summit Therapeutics
Deal Size : $3.8 million
Deal Type : Collaboration
Summit Therapeutics to Receive $1.0 Million Milestone Payment
Details : The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Summit Therapeutics
Deal Size : $3.8 million
Deal Type : Collaboration